What's happening
This bill restores Medicaid pharmacy benefits to the state program, repealing provisions that shifted them to managed care plans.
Why it matters
Potential for Lower Drug Costs. By restoring pharmacy benefits to the state-run program, New York could leverage its larger purchasing power to negotiate bigger rebates and discounts from drug manufacturers, potentially reducing overall Medicaid drug spending.
Uniform Drug Access and Oversight. Centralizing pharmacy benefits under state management means all Medicaid participants—including those in managed care—will have the same drug coverage rules, prior authorization processes, and access to the state's preferred drug and clinical review programs, potentially improving consistency and transparency.
Impact on 340B Providers. The bill preserves a carve-out for prescriptions filled through the federal 340B drug pricing program, ensuring that safety-net providers (like certain hospitals and clinics) can continue to benefit from 340B discounts, though with new requirements for prior authorization and clinical review.
Changes for Patients and Providers. Patients and prescribers may notice changes in how drugs are approved and dispensed, with stricter adherence to state-approved formularies and review processes. This could affect drug choices, generic substitution requirements, and off-label prescribing, which may require more justification and be subject to additional scrutiny.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Who cares
Medicaid managed care and managed long-term care plans
Plans would pay for enrollees’ 340B prescriptions and reimburse the Department of Health for its net prescription drug costs, with a reimbursement component included in capitation payments.
Medicaid enrollees
Covered prescriptions would generally be provided and paid for through the preferred drug and clinical drug review programs, with separate payment rules for managed care enrollees’ 340B prescriptions.
Prescribers
Their decisions to use nonpreferred drugs would no longer be final when mandatory generic substitution applies or the proposed use lacks FDA-approved labeling or compendia support.
Department of Health
The department would administer the prescription drug framework and receive reimbursements from managed care plans, while the bill seeks to strengthen Medicaid’s ability to negotiate manufacturer rebates.
Headline styles
Restore Medicaid Drug Benefits
Plain English, a few words. Used as the page title.
Sponsors
1 Co-sponsor
History
- Referred to health
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Restore Medicaid Drug Benefits
In Assembly Committee · Ways And Means · Sponsor Richard Gottfried
Full text
2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
9043
IN SENATE
May 5, 2022
Introduced by Sens. RIVERA, REICHLIN-MELNICK -- read twice and ordered printed, and when printed to be committed to the Committee on Health
AN ACT to amend the social services law, in relation to prescription drugs eligible for Medicaid coverage; to amend the public health law, in relation to prior authorization under the preferred drug program; to repeal certain provisions of part FFF of chapter 56 of the laws of
2020 directing the department of health to remove the pharmacy benefit from the managed care benefit package, relating to restoring such benefits; and to repeal certain provisions of the social services law, relating to coverage for certain prescription drugs under Medicaid managed care programs
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Legislative findings. This legislature finds that the costs of many prescription drugs in the market have been escalating unreasonably. The preferred drug program and the clinical drug review program under the public health law provide effective mechanisms for assuring access to quality, effective and safe drugs to patients at reasonable cost. Providing prescription drugs to Medicaid managed health care provider participants through these programs will maximize the Medicaid program's ability to negotiate more substantial rebates with drug manufacturers (effectively, lower prices), while protecting Medicaid managed care provider participants.
§ 2. Sections 1 and 1-a of part FFF of chapter 56 of the laws of 2020, relating to prescription drugs under the Medicaid program, are REPEALED.
§ 3. The social services law is amended by adding a new section 365-i to read as follows:
§ 365-i. Prescription drugs in Medicaid. 1. The definitions of terms in section two hundred seventy of the public health law shall apply to this section. As used in this section, unless the context clearly requires otherwise, "managed care provider" means a managed care provider under section three hundred sixty-four-j of this article, or a managed long term care plan under section forty-four hundred three-f of the public health law.
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD11099-03-2
2. Prescription drugs eligible for reimbursement under this article shall be provided and paid for under the preferred drug program and the clinical drug review program under title one of article two-A of the public health law, except as otherwise provided in subdivision three of this section.
3. This subdivision applies where the eligible individual is enrolled in a managed care provider and a prescription for the eligible individual is made under section 340B of the federal Public Health Service Act (the "340B program"). The managed care provider shall pay for the drugs under the 340B program. However, the prescription shall be subject to section two hundred seventy-three (preferred drug program prior authorization) and section two hundred seventy-four (clinical drug review program) of the public health law.
4. The managed care provider shall account to and reimburse the department for the net cost to the department for prescription drugs provided to eligible individuals who receive medical services from the managed care provider. Capitation payments by the department to such managed care provider shall include a component for reimbursements paid under this subdivision.
§ 4. Paragraph (b) of subdivision 3 of section 273 of the public health law, as added by section 10 of part C of chapter 58 of the laws of 2005, is amended to read as follows:
(b) In the event that the patient does not meet the criteria in paragraph (a) of this subdivision, the prescriber may provide additional information to the program to justify the use of a prescription drug that is not on the preferred drug list. The program shall provide a reasonable opportunity for a prescriber to reasonably present his or her justification of prior authorization. If, after consultation with the program, the prescriber, in his or her reasonable professional judgment, determines that the use of a prescription drug that is not on the preferred drug list is warranted, the prescriber's determination shall be final. However, the prescriber's determination shall not be final: (i) where the preferred drug is a generic drug subject to subparagraph (i) of paragraph (a-1) of subdivision four of section three hundred sixty-five-a of the social services law (mandatory generic substitution), and even if the prescriber has indicated that the prescription shall be dispensed as written; or (ii) if it is for the use of a drug that is not consistent with food and drug administration-approved labeling or supported by one or more official Compendia references, including, but not limited to, the American Hospital Formulary Service (AHFS), the DRUGDEX Drug Information System and the United States Pharmacopeia.
§ 5. Subdivisions 25, 25-a, 26 and 26-b, and paragraph (u) of subdivision 4 of section 364-j of the social services law are REPEALED.
§ 6. Severability. If any provision of this act, or any application of any provision of this act, is held to be invalid, or to violate or be inconsistent with any federal law or regulation, that shall not affect the validity or effectiveness of any other provision of this act, or of any other application of any provision of this act, which can be given effect without that provision or application; and to that end, the provisions and applications of this act are severable.
§ 7. This act shall take effect immediately, except that sections one through five of this act shall take effect on the one hundred eightieth day after they shall have become a law. Effective immediately, the commissioner of health shall make regulations and take other actions reasonably necessary to implement this act when it takes effect.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Sponsor's memo
Title of bill
An act to amend the social services law, in relation to prescription drugs eligible for Medicaid coverage; to amend the public health law, in relation to prior authorization under the preferred drug program; to repeal certain provisions of part FFF of chapter 56 of the laws of 2020 directing the department of health to remove the pharmacy benefit from the managed care benefit package, relating to restoring such benefits; and to repeal certain provisions of the social services law, relating to coverage for certain prescription drugs under Medicaid managed care programs
Purpose or general idea of bill
To provide the Medicaid drug benefit through utilization of the preferred drug program (PDP) under Public Health Law Art. 2-A, rather than through individual Medicaid managed care plan drug benefits.
Summary of specific provisions
Section 1 provides for legislative findings.
Read the full memo (852 words)
Section 2 repeals sections 1 and 1-a of part FF of chapter 56 of the laws of 2020, related to prescription drugs under the Medicaid program.
Section 3 amends the social services law to add a new section 365-i related to prescription drugs in the Medicaid program. Prescription drugs eligible for reimbursement in accordance with this article shall be paid for by the preferred drug and clinical drug review programs. This shall apply for individuals enrolled in a managed care provider, and a prescription made under the 340B program. The provider shall pay for drugs provided under the 340B program and shall reimburse the Department of Health for the net cost to the department for prescription drugs provided.
Section 4 amends subdivision 3 of section 273 of the public health law to provide those prescriptions would be subject to the "prescriber prevails" provisions of the preferred drug program.
Section 5 repeals subdivisions 25, 25-a, 26, 26-b and paragraph u of subdivision 4 of section 364-j of the social services law.
Section 6 provides for a severability clause.
Section 7 provides for the effective date, which is immediately with the exception of sections 1, 2, 3 4, and 5 which shall take effect 180 days after it shall become a law.
Justification
The Preferred Drug Program was established in 2005. Under the PDP, the clinical drug review board (DRB) evaluates the clinical effectiveness and safety of drugs, the potential impact on patient care and on the health of special populations considering the latest peer-reviewed research. The DRB may place a drug or class of drugs either on the preferred drug list (PDL) or require prior authorization, which if declined, may be overcome using "prescriber prevails," so that a pres- criber can make sure that the patient receives the needed medication. The PDP initially administered the drug benefit for the whole Medicaid program, including Medicaid managed care.
During the several years that the PDP operated for all Medicaid patients, very few prescriptions were for non-preferred drugs because (a) prescribers had confidence in the legitimacy of the list, (b) the required consultation with the system was enough of a "speed bump" that prescribers stuck to the list unless they felt strongly otherwise, and drug companies were willing to pay the required rebates to get their drugs on the list, at an estimated average of $2B per year.
In 2011, the Legislature enacted the Cuomo administration proposal to end the carve-out and instead have each Medicaid managed care plan nego- tiate on its own with drug companies. The administration insisted the managed care plans could do a better job of negotiating, even though the state was negotiating for a much larger population than any one managed care plan. In 2020, the administration reversed course, enacting a plan to return the drug benefit to the PDP by May of 2021, and in the inter- im, find a solution to the problem faced by providers in the federal 340B program who would lose operating revenue from being carved out from managed care. With the 340B issue still not resolved by March 2021, the administration agreed to a delay of the carve-out plan for two years.
This bill would restore to the PDP the power to negotiate drug prices for the entire Medicaid population over six million "covered lives" - by having the PDP administer the drug benefit, at the same time keeping the 340B program intact within managed care. Managed care plan enrollees would use their plan membership card for drug benefits. Medicaid would bill each Medicaid managed care plan for the drugs provided to its enrollees and return the amount through the premium rate that the state pays the plans. This would be consistent with integrated care, care coordination, and "value-based" payment models. It would more effec- tively hold the managed care plan or provider network accountable for the total cost of care, while still giving the health plan (and the state) the benefit of lower drug prices.
Prior legislative history
2015-2016: A.9271 - reported to Ways and Means committee
2017-2018: A.4233 - reported to Ways and Means committee
Fiscal implications
Undetermined savings.
EFFECTIVE DATE:; Immediately, except for sections 1-5 which shall be effective one hundred and eighty days after becoming law.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.